1159266-37-1
1159266-37-1 structure
- Name: Mogamulizumab
- Chemical Name: Mogamulizumab
- CAS Number: 1159266-37-1
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways GPCR/G Protein CCR
- Create Date: 2023-01-18 23:16:01
- Modify Date: 2024-04-06 11:42:51
-
Mogamulizumab (KW-0761) is a defucosylated humanized recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL)[1][2][3].
| Name | Mogamulizumab |
|---|
| Description | Mogamulizumab (KW-0761) is a defucosylated humanized recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL)[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
CCR4 |
| In Vitro | Mogamulizumab (10 μg/mL, 24 h) induces ADCC activity against CCR4-positive cell lines (SNT8, SNT16, SNK6, and KAI3) in the presence of PBMCs[2]. Mogamulizumab (10 μg/mL, 3 days) reduces the human T-lymphotropic virus type 1 (HTLV-1) proviral load and inhibits spontaneous proliferation in PBMCs from patients with HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP)[3]. Mogamulizumab (1 μg/mL, 5 days) eliminates the CD4+CCR4+ T cells in cultured PBMCs from patients with HAM/TSP[3]. |
| In Vivo | Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) together with PBMC transplantation inhibits the growth of EBV-positive NK-cell lymphomas in a murine xenograft model[2]. Mogamulizumab (0.1 mg/kg, i.v., every other day) together with canine PBMCs (every fourth day)), inhibits tumor growth in canine bladder cancer-engrafted mouse model[4]. Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4+CCR4+ T cells, with no adverse effect in dogs[4]. Animal Model: Murine xenograft model, constructed by using the immunodeficient NOG mouse and the EBV-positive NK-cell lymphoma cell line (SNK6)[2] Dosage: 1 mg/kg Administration: Intraperitoneal injection (i.p.), together with PBMC transplantation; twice per week for 4 weeks. Result: Suppressed Tumor growth with vacuolar degeneration. |
| References |
| No Any Chemical & Physical Properties |